Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions

Journal of the National Cancer Institute

Volumn 91, Issue 11, 1999, Pages 954-960

  Liaw, Kai Li ^a   Glass, Andrew G ^b   Manos, M Michele ^c,h   Greer, Catherine E ^c   Scott, David R ^b   Sherman, Mark ^d   Burk, Robert D ^e   Kurman, Robert J ^d   Wacholder, Sholom ^a   Rush, Brenda B ^b   Cadell, Diane M ^f   Lawler, Patti ^b   Tabor, David ^f,i   Schiffman, Mark ^a,g  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KAISER PERMANENTE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f WESTAT   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h DIVISION OF RESEARCH   (United States)

ⁱ Allied Technology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ARTICLE; CANCER CYTODIAGNOSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

EID: 0033516292     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.11.954     Document Type: Article

References (24)

1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
2. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85: 958-64.
3. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 64. Human papillomaviruses. Lyon (France): IARC; 1995.
4. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells Mol Diagnos Hum Cancer 1989;7: 209-14.
5. Hildesheim A, Gravitt P, Schiffman MH, Kurman RJ, Barnes W, Jones S, et al. Determinants of genital human papillomavirus infection in low-income women in Washington, D.C. Sex Transm Dis 1993;20:279-85.
6. Snijders PJ, van den Brule AJ, Schrijnemakers HF, Snow G, Meijer CJ, Walboomers JM. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol 1990;71(Pt 1):173-81.
7. Qu W, Jiang G, Cruz Y, Chang CJ, Ho GY, Klein RS, et al. PCR detection of human papillomavirus: comparison between MY09/ MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997;35:1304-10.
8. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992; 327:1272-8.
9. Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;61: 306-11.
10. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
11. Wideroff L, Schiffman MH, Nonnenmacher B, Hubbert N, Kirnbauer R, Greer CE, et al. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995;172:1425-30.
12. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop. JAMA 1989;262; 6:931-4.
13. Vermund SH, Schiffman MH, Goldberg GL, Ritter DB, Weltman A, Burk RD. Molecular diagnosis of genital human papillomavirus infection: comparison of two methods used to collect exfoliated cervical cells. Am J Obstet Gynecol 1989;160:304-8.
14. Sherman ME, Schiffman MH, Lorincz AT, Manos MM, Scott DR, et al. Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol 1994;102:182-7.
15. Tachezy R, Van Ranst MA, Cruz Y, Burk RD. Analysis of short novel human papillomavirus sequences. Biochem Biophys Res Commun 1994;204:820-7.
16. Ho GY, Burk RD, Klein RS, Kadish AS, Chang CJ, Palan P, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
17. Jiang G, Qu W, Ruan H, Burk RD. Elimination of false-positive signals in enhanced chemiluminescence (ECL) detection of amplified HPV DNA from clinical samples. Biotechniques 1995;19:566-8.
18. Breslow NE, Day NE. Statistical methods in cancer research. Volume 1 - The analysis of case-control studies. IARC Sci Publ 1980;32: 270-6.
19. Hsing AW, Burk RD, Liaw KL, Chen CJ, Zhang T, Schiffman M, et al. Interlaboratory agreement in a polymerase chain reactionbased human papillomavirus DNA assay [letter]. Cancer Epidemiol Biomarkers Prev 1996; 5:483-4.
20. Bauer HM, Hildesheim A, Schiffman MH, Glass AG, Rush BB, Scott DR, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 1993;20:274-8.
21. Rosenfeld WD, Vermund SH, Wentz SJ, Burk RD. High prevalence rate of human papillomavirus infection and association with abnormal papanicolaou smears in sexually active adolescents. Am J Dis Child 1989;143:1443-7.
22. Schiffman MH, Sherman ME. HPV testing to improve cervical cancer screening. In: Srivastava S, Lippman SM, Hong WK, Mulshine JL, editors. Molecular markers of early detection of cancer. Armonk (NY): Futura Publishing Co.; 1994. p. 265-77.
23. Oriel JD. Sex and cervical cancer. Genitourin Med 1988;64:81-9.
24. Franco EL, Villa LL, Rahal P, Ruiz A. Molecular variant analysis as an epidemiological tool to study persistence of cervical human papillomavirus infection [letter]. J Natl Cancer Inst 1994;86:1558-9.